While other MediaPost newsletters and articles remain free to all ... our new Research Intelligencer service is reserved for paid subscribers ...
Subscribe today to gain access to every Research Intelligencer article we publish as well as the exclusive daily newsletter, full access to The MediaPost Cases, first-look research and daily insights from Joe Mandese, Editor in Chief.
Become a free MediaPost member now to read this article
Unlimited articles every day
Keep up-to-date with media, marketing and advertising news
Invitations to exclusive industry events and research
Subscribe to Marketing Daily
Bristol-Myers Squibb Buys Kosan Biosciences
May 30, 2008
The acquisition of the cancer therapeutics company is expected to enhance Bristol-Myers Squibb's pipeline with compounds in two classes of anticancer agents: novel Hsp90 (heat shock protein 90)
inhibitors and epothilones, per the company.
The transaction, with a net aggregate purchase price of approximately $190 million after deducting Kosan's projected net cash balance at June
30, has been unanimously approved by the boards of directors of both companies.